Cord Blood News 12.14 April 16, 2020 | |
| |
TOP STORYAdministration of MSCs overexpressing CREB1-NRF2 target genes alleviated graft-versus-host disease (GVHD) in a humanized mouse model, resulting in improved survival, decreased weight loss, and reduced histopathologic damages in GVHD target organs. [Sci Adv] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists investigated the role of transforming growth factor‐beta (TGF-β) in the therapeutic effect of human umbilical cord blood-derived MSCs on atopic dermatitis. [Stem Cells] Abstract Researchers compared the phenotypic profiles of human regulatory T cells (Tregs) isolated from cord blood (CB) versus the more traditional source, adult peripheral blood (APB). CB Tregs were more diverse in T cell receptor repertoire and homogenous in phenotype, and contained fewer effector-like cells in contrast with APB Tregs. [Front Immunol] Abstract Both mRNA and protein analyses showed that prolactin increased mothers against decapentaplegic homolog 7 (SMAD7) in CD34+ prolactin receptor positive myeloid cells, which reduced the production of transforming growth factor beta 1, a cytokine known to inhibit CD56+ cell development. [Sci Rep] Full Article Hematopoietic stem cell transplantation (HSCT) in patients with Griscelli syndrome type 2 was potentially curative with long-term disease-free survival. Early HSCT before the development of the accelerated phase was associated with a better outcome. [Bone Marrow Transplant] Abstract The authors demonstrated that a simple solution containing a pH buffering reagent, calcium, magnesium and glucose could be used as a cost-effective storage solution for umbilical cord delivery and efficient MSC isolation. [Biotechniques] Full Article The collagen scaffold administered with human umbilical cord MSCs (hUCMSCs) markedly increased the number of endometrial glands and reduced the area of fibrosis compared with either the collagen scaffold or hUCMSCs alone. [Gynecol Obstet Invest] Abstract Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News. | |
| |
REVIEWSWharton’s jelly is abundant in MSCs that express CD105, CD73, CD90, Oct-4, Sox-2, and Nanog among others, and have the ability to differentiate into osteogenic, adipogenic, chondrogenic, and other lineages. Moreover, Wharton’s jelly-derived MSCs do not express MHC-II and exhibit immunomodulatory properties, which makes them a good alternative for allogeneic and xenogeneic transplantations in cellular therapies. [J Clin Med] Full Article Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
INDUSTRY NEWSQueen’s University Leading Cell Therapy Clinical Trial to Help Improve Outcomes in COVID-19 Patients Researchers at Queen’s University Belfast are leading a UK-wide clinical trial, offering an innovative cell therapy treatment for COVID-19 patients with acute respiratory failure. [Queen’s University Belfast] Press Release Predictive Biotech announced that it submitted an Emergency Use Authorization application with the FDA for the immediate use of MSCs derived from umbilical cord tissue for the treatment of acute respiratory distress syndrome, secondary to SARS-CoV-2, coronavirus disease 2019 (COVID-19). [Predictive Biotech] Press Release | |
| |
POLICY NEWS‘Short-Sighted.’ Health Experts Decry Trump’s Freeze on US Funding for WHO as World Fights Pandemic President Donald Trump said he will suspend US funding to the World Health Organization (WHO) pending a 60- to 90-day investigation into how the agency has handled the response to the COVID-19 pandemic. [ScienceInsider] Editorial How Scientists Can Volunteer to Help Fight COVID-19 Around the world, bench scientists other than those actively studying the pandemic have largely been forced to scale back or even shut down their experiments out of COVID-19 precautions. But that doesn’t mean their skills and expertise can’t contribute to the worldwide effort to address the disease. [The Scientist] Editorial
| |
EVENTSIn light of COVID-19, many conferences are being cancelled or postponed. As such: We are suspending new event postings in our newsletters and on Twitter. Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Director – Blood Research Institute (Versiti) Research Technician – Hematopoietic Stem Cells (Karolinska Institutet) Postdoctoral Positions – Leukemia (Temple University School of Medicine) Postdoctoral Position – Hematopoietic Stem Cells (Lund University) Postdoctoral Researcher – Hematologic Malignancies (Northwestern University) Postdoctoral Position – Hematopoietic Stem Cell Biology (Columbia University Medical Center) Postdoctoral Positions – Cancer Research (Moores Cancer Center, UC San Diego) Postdoctoral Researcher – Leukemia (Universitätsklinikum Carl Gustav Carus Dresden) Postdoctoral Scientist – Stem Cell Biology (Cancer Research UK Manchester Institute) Laboratory Director – Cord Blood Processing (PerkinElmer) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|